Precision BioSciences, Inc. DTIL PHARMA
Company Overview
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Why Investors Should Care
Revenue has grown at a 17.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $34.26M (-50.1% YoY); net profit $-45.72M.
- Trailing 12 Months Year-on-year growth — revenue -50.1%, earnings -738.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.80% |
| 1 Year: | -50.12% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -737.98% |
Stock Price Performance
| 1 Year: | +57.78% |
| 6 Months: | +57.11% |
| 3 Months: | +9.31% |
| 1 Month: | -1.20% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)41.83 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 17.8% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DTIL Precision BioSciences, Inc. PHARMA | 7.40 | -5.61 | $204.25M | 0.00% | -35.84% | -135.15% | 17.80% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.53M | 1.87M | 2.54M | 5.46M | 5.39M | 4.87M | 7.00M | 1.08M | 7.36M | 16.35M | 68.81M | 24.04M | 3.32M | 3.82M | 7.36M | 8.78M | 19.79M | 13.12M | 17.58M | 49.90M | 576.00K | 29.00K | 18.00K | 13.00K | 10.84M | 0 |
| Operating Income | -9.23M | -12.12M | -10.45M | -19.49M | -23.87M | -21.98M | -27.50M | -32.81M | -26.04M | -18.74M | 21.63M | -11.54M | -27.34M | -29.55M | -14.68M | -13.35M | -3.13M | -12.36M | -4.19M | 24.15M | -21.27M | -22.11M | -21.88M | -20.67M | -9.07M | -19.16M |
| Net Income | -9.01M | -11.83M | -9.76M | -31.78M | -19.44M | -20.74M | -26.84M | -32.70M | -26.02M | -18.69M | 21.66M | -11.28M | -28.17M | -31.04M | -23.95M | -25.06M | -11.89M | -8.08M | 8.59M | 32.75M | -16.43M | -20.57M | -23.52M | -21.77M | -18.44M | -32.65M |
| Diluted EPS | - | - | - | - | - | - | - | -0.63 | - | - | 0.36 | -0.19 | -0.46 | -0.46 | -0.22 | -6.75 | -3.13 | -2.10 | 1.70 | 4.67 | -2.25 | -2.21 | -2.13 | -1.84 | -0.75 | -1.26 |
| R&D Expense | 8.12M | 10.87M | 9.74M | 19.96M | 22.76M | 19.79M | 24.88M | 25.18M | 24.87M | 25.59M | 37.23M | 25.94M | 19.97M | 22.94M | 11.76M | 11.05M | 13.09M | 15.85M | 13.34M | 17.23M | 13.08M | 13.59M | 12.77M | 13.35M | 13.11M | 12.39M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.88M | 22.24M | 24.29M | 115.53M | 25.10M | 48.73M | 68.70M | 34.26M |
| Operating Income | -47.91M | -87.20M | -109.83M | -39.38M | -62.31M | -43.74M | -26.16M | -52.15M |
| Net Income | -46.04M | -92.88M | -109.01M | -30.60M | -111.64M | -61.32M | 7.17M | -45.72M |
| Diluted EPS | - | - | - | -0.52 | -38.10 | -15.96 | 1.04 | -3.56 |
| R&D Expense | 45.12M | 82.42M | 98.06M | 115.24M | 46.12M | 53.38M | 59.56M | 54.17M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 138.60M | 235.23M | 150.16M | 211.50M | 238.17M | 159.78M | 136.39M | 154.42M |
| Total Equity | -26.37M | 39.96M | 138.31M | 44.42M | 91.17M | 60.43M | 18.86M | 56.39M | 92.25M |
| Cash & Equivalents | - | 103.19M | 180.89M | 89.80M | 143.66M | 189.58M | 116.68M | 85.90M | 110.82M |
| Long Term Debt | - | - | - | - | 2.48M | 22.22M | - | - | - |
| Total Liabilities | - | 98.64M | 96.92M | 105.73M | 120.33M | 177.74M | 140.92M | 80.00M | 62.17M |
| Current Liabilities | - | 14.07M | 26.93M | 42.83M | 35.98M | 59.66M | 49.99M | 14.98M | 8.91M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -51.72M | -71.02M | -87.39M | -10.85M | -45.75M | -84.11M | -58.45M | -65.84M |
| Investing Cash Flow | -15.66M | -24.67M | -5.03M | -5.80M | -3.32M | 5.83M | -215.00K | -634.00K |
| Financing Cash Flow | 107.78M | 173.37M | 1.33M | 70.52M | 94.98M | 5.39M | 50.45M | 95.16M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | -440.2% | -392.1% | -452.2% | -34.1% | -248.3% | -89.8% | -38.1% | -152.2% |
| Net Margin % | -423.0% | -417.6% | -448.9% | -26.5% | -444.8% | -125.8% | 10.4% | -133.4% |
| ROE % | -115.2% | -67.1% | -245.4% | -33.6% | -184.7% | -325.1% | 12.7% | -49.6% |
| ROCE % | -38.5% | -41.9% | -102.3% | -22.4% | -34.9% | -39.8% | -21.5% | -35.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Aberdeen Group plc | 8.08% | 2.23M | $14.88M |
| 2 | Bleichroeder LP | 7.31% | 2.02M | $13.46M |
| 3 | Octagon Capital Advisors LP | 4.89% | 1.35M | $9.00M |
| 4 | Boothbay Fund Management, LLC | 4.88% | 1.35M | $8.98M |
| 5 | Blackrock Inc. | 4.25% | 1.17M | $7.82M |
| 6 | Vanguard Capital Management LLC | 4.04% | 1.12M | $7.45M |
| 7 | Lynx1 Capital Management Lp | 3.44% | 950.47K | $6.34M |
| 8 | Driehaus Capital Management, LLC | 3.43% | 946.71K | $6.31M |
| 9 | Empery Asset Management, LP | 2.81% | 776.09K | $5.18M |
| 10 | Affinity Asset Advisors, Llc | 2.34% | 646.58K | $4.31M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DTIL
Precision Biosciences Stock Price Forecast. Should You Buy DTIL? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE11RlRjb2FQaExscWxjR0ZfeHY1dVY5Vkd5NzVtdEhfaE1VaGR3YTAtaWcxY054M1E0X3E3NWZlUzJGZm5JY0dYMg?oc=5" target="_blank">Precision Biosciences Stock Price Forecast. Should You Buy DTIL?</a>&…
Behavioral Patterns of DTIL and Institutional Flows - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQU3NPZzBzVTlFbFpsalNFMnBSNnZhMkZtZWg1aW9XSVNOTE5TWFdPdURIMkxZSVc2NURuSGl4aGRNRXJDNEtydlBsamVjNVpWWm1fLWxsbUtqX1pBSFZaNWtXbl9rVUJ4UnREbk5nZTd2R21ucjFOZnZ2QXJKRkduOFVVdXIxeUlEbVZSb0…
Precision BioSciences: Promising HBV Editing Evidence (NASDAQ:DTIL) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNTktJRjJlRjBhZ09vV01lTGNDVDJWeWZ0WUoxQVZrX2tOQmpzTDgzeXhid2NIZUl0b25lX3YtUU9lcEtKRERTeC1zNXM4YnhQUGlmZVNDZFBkNHB2RXN2R3g0YVRQekFmWmtBRUFESDZzM2ctemRVaTZrYlNKRXZGUnFiWlJiMWpRT3JYak…
DTIL Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBQNnRhSkZjN1RMV0syazBEWU9ZeHVvSkozNTZZelU3MTBZV1pKVmIwRTZWa1p1UHJqQjhtNFBNcnZnQVY1QmdTUWtlWGdYVG0tVFI0S3NlT1BUQVBmSnZiTk5wdXh4aENiNi0tSmt5dGc1WU5hdTZjSjNB?oc=5" target="_blank">DTI…
A gene-editing treatment for Duchenne muscular dystrophy doses its first patient - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOUDdBR0dBVGNBZlc1VVhFQllyYXVQb1ZKTVd5c2dDal9kcGNGajItaU91U3ktZ1JrWjY5ZEFqWm5fNjRNNDFjd29HejJxXzVlMWRiNTBSSVktMDJnNFAtNTNzbnFhOE02VkZhbGFGT3NzbFgyNlkxZ0pNSFh1Ull1T0ZEUTdzUUlOMlRKc2…
$DTIL stock is up 11% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNVnl4bWdscEd3VWk2SXcyajhzWnJQb0djX1JQN25yakJENUZnTzBidEh3cUN6eDlwRjdWR2JIODMwbHMyYmhwRldMRU1oWmVtc3dSRjdockVWN3V3LVNYWm9vaTlHclFQbXF4VDhkV1lkNE1mbmhYVTJ2M21XNTRzcWJQbVhvQzFCaVFYcm…
DTIL — Frequently Asked Questions
What is the current share price of Precision BioSciences, Inc. (DTIL)?
As of 2026-09-19 21:16 PDT, Precision BioSciences, Inc. (DTIL) trades at $7.40 on NasdaqCM. Its 52-week range is $3.57 to $9.28.
What is the market capitalisation of DTIL?
Precision BioSciences, Inc. (DTIL) has a market capitalisation of $204.25M on NasdaqCM.
What is the P/E ratio of DTIL?
DTIL trades at a trailing price-to-earnings (P/E) ratio of -5.61. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.23.
What is the return on equity (ROE) of DTIL?
DTIL has a return on equity (ROE) of -135.15%. Its return on capital employed (ROCE) is -35.84%.
Is DTIL a good stock to buy?
This page provides a data-driven analysis of Precision BioSciences, Inc. (DTIL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.